Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study

Sponsor
University of Dublin, Trinity College
Study ID
NCT07196020
Status
Recruiting
Apply to this trial

Conditions

  • Cancer
  • Venous Thromboembolism

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Cancer patients are at higher risk of getting a blood clot (known as venous thromboembolism (VTE)) especially during chemotherapy and some patients are more at risk than others. These clots can be prevented by using blood thinners (known as anticoagulants) but these are not suitable for everyone as they also carry a risk of bleeding. This study aims to identify which chemotherapy patients are most at risk of a blood clot and at what point in their treatment this is likely to happen. In this project biomarkers in the blood that are involved in blood clotting will be measured in cancer patients at four stages during chemotherapy to see how the biomarkers change during treatment. The blood samples for these tests are taken at the same time as the normal routine blood tests done before a chemotherapy cycle. Biomarker levels will be compared between those patients who subsequently get a VTE and those who do not get a VTE. This will help develop a biomarker based blood test to predict clots during chemotherapy. The biomarker based test will also be compared with other methods of predicting VTE in cancer patients which are currently in use. In the future, this blood test might be used to see if patients are at high risk of a clot during chemotherapy and provide a method to optimise the use of preventative anticoagulants in cancer patients during chemotherapy.

Key Dates

First listed
Sep 29, 2025
Start date
Oct 1, 2025
Status verified
Sep 2025
Primary completion
Mar 1, 2029
Completion
Sep 1, 2029

Study Design

Enrollment
380 participants (estimated)

Arms

  • Arm: Cancer patients undergoing chemotherapy
    Lung, ovarian and pancreatic cancer patients undergoing chemotherapy.

Primary Outcome Measure

Venous thromboembolism [ Time Frame: From initiation of treatment to 12 weeks from last sample time point ]

Central Contacts

Related Studies